Monitor the offering close on February 27, 2026, and watch for any subsequent announcements regarding the specific allocation of the $107.6 million in net proceeds, particularly how much will be directed toward advancing Larimar's clinical programs versus general corporate expenses.
Price Chart
Executive Summary
Larimar Therapeutics is conducting a follow-on public offering of 20 million shares at $5.00 per share, with underwriters exercising their full option to purchase an additional 3 million shares, resulting in expected net proceeds of approximately $107.6 million. The company plans to use the proceeds for general corporate purposes, including advancing its clinical programs and expanding operations.
Key Financial Metrics
Key Facts
- Larimar Therapeutics is offering 20 million shares of common stock at $5.00 per share
- Underwriters exercised their full option to purchase an additional 3 million shares
- Expected net proceeds after underwriting discounts and commissions are approximately $107.6 million
- J.P. Morgan Securities LLC and Guggenheim Securities, LLC are acting as joint bookrunning managers
- The offering is expected to close on February 27, 2026, subject to customary closing conditions
Financial Impact
Approximately $107.6 million in net proceeds after underwriting discounts and commissions from the sale of 23 million shares at $5.00 per share
Risk Factors
- Dilution to existing shareholders from the issuance of 23 million new shares
- Potential downward pressure on stock price due to increased share supply
- Uncertainty around how effectively the company will deploy the raised capital
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-077646 |
| Document: d120172d8k.htm | 0001193125-26-077646 |
| Document: d120172dex51.htm | 0001193125-26-077646 |
| Document: 0001193125-26-077646-index-headers.html | 0001193125-26-077646 |
| Document: 0001193125-26-077646-index.html | 0001193125-26-077646 |
| Document: 0001193125-26-077646.txt | 0001193125-26-077646 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
May 14, 2026 20w ago | 8-K | $3.89 $4.01 | ▲ +3.08% | ▼ −0.50% | $2.96 (−23.91%) |
May 14, 2026 20w ago | Press Release | $3.89 $4.01 | ▲ +3.08% | ▼ −0.50% | $2.96 (−23.91%) |
Mar 19, 2026 28w ago | Press Release | $4.47 $3.59 | ▼ −19.69% | ▼ −34.03% | $2.96 (−33.78%) |
Feb 27, 2026 31w ago | 8-K | $5.31 $3.47 | ▼ −34.65% | ▼ −44.04% | $2.96 (−44.26%) |
Feb 27, 2026 31w ago | Insider Cluster | $5.31 $3.47 | ▼ −34.65% | ▼ −44.04% | $2.96 (−44.26%) |
Feb 27, 2026 31w ago | Insider Cluster | $5.31 $3.47 | ▼ −34.65% | ▼ −44.04% | $2.96 (−44.26%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access